1. Home
  2. GCTS vs ADCT Comparison

GCTS vs ADCT Comparison

Compare GCTS & ADCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo GCT Semiconductor Holding Inc.

GCTS

GCT Semiconductor Holding Inc.

N/A

Current Price

$1.11

Market Cap

185.8M

Sector

Finance

ML Signal

N/A

Logo ADC Therapeutics SA

ADCT

ADC Therapeutics SA

N/A

Current Price

$1.32

Market Cap

192.7M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
GCTS
ADCT
Founded
1998
2011
Country
United States
Switzerland
Employees
N/A
N/A
Industry
Blank Checks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
185.8M
192.7M
IPO Year
2021
2019

Fundamental Metrics

Financial Performance
Metric
GCTS
ADCT
Price
$1.11
$1.32
Analyst Decision
Strong Buy
Buy
Analyst Count
2
5
Target Price
$3.13
★ $3.33
AVG Volume (30 Days)
★ 1.7M
1.2M
Earning Date
11-12-2026
11-09-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 30.86
EPS
★ N/A
N/A
Revenue
$2,866,000.00
★ $81,357,000.00
Revenue This Year
$76.29
N/A
Revenue Next Year
$648.00
$25.89
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
★ 14.85
52 Week Low
$0.96
$0.78
52 Week High
$3.93
$4.98

Technical Indicators

Market Signals
Indicator
GCTS
ADCT
Relative Strength Index (RSI) 38.49 42.55
Support Level $1.00 $0.97
Resistance Level $1.43 $1.45
Average True Range (ATR) 0.15 0.17
MACD 0.01 -0.04
Stochastic Oscillator 23.83 8.80

Price Performance

Historical Comparison
GCTS
ADCT

About GCTS GCT Semiconductor Holding Inc.

GCT Semiconductor Holding Inc is a designer and supplier of 5G and 4G LTE semiconductor solutions. It enabled fast and reliable 4G LTE connectivity to numerous commercial devices such as CPEs, mobile hotspots, routers, M2M applications, and smartphones, etc. The system-on-chip solutions integrate radio frequency, baseband modem, and digital signal processing functions, therefore offering complete 4G and 5G platform solutions with small form factors, low power consumption, high performance, high reliability, and cost-effectiveness. Geographically, operates in South Korea and the United States, with maximum revenue from the USA.

About ADCT ADC Therapeutics SA

ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's FDA-approved and marketed product, ZYNLONTA (loncastuximab tesirine), is a CD19-directed antibody and alkylating agent conjugate indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. Additionally, the company's development pipeline comprises LOTIS-2, LOTIS-5, LOTIS-7, and ADCT-241, being developed as potential therapies for different cancer diseases. Geographically, the firm generates maximum revenue from the United States, followed by Europe, the Middle East and Africa (EMEA).

Share on Social Networks: